NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)
NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma
NCT04891809: Phase 2 - Isatuximab in Combination With Rd Compared to Rd in Elderly NDMM
NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint
NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dex in TIE NDMM
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04822337: Phase 1/2 - Study of Carfilzomib, Len, Dex & Belantamab Mafodotin in Multiple Myeloma
NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS RRMM Myeloma
NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04566328: Phase 3 - Testing the Use of Combination Therapy in NDMM, the EQUATE Trial - EAA181
NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)
NCT04430894: Phase 2: KRDI in Transplant-Eligible MM